Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PACB | 144 | bearish | 5/10 | Director James R. Gibson II filed a Form 144 notice of intent to sell up to 661,815 shares of Pacific Biosciences of Cal | Oct 6, 2026 |
| BMRN | 8-K | bearish | 6/10 | BioMarin disclosed that its Q3 2026 results will include ~$283M in pre-tax acquired IPR&D charges from the Alesta Therap | Oct 6, 2026 |
| ADPT | 144 | neutral | 2/10 | Susan Bobulsky, an officer of Adaptive Biotechnologies, filed a Form 144 on October 6, 2026, indicating intent to sell 6 | Oct 6, 2026 |
| ARTV | 144 | neutral | 3/10 | Fred Aslan, a Director and Officer of Artiva Biotherapeutics, filed a Form 144 notice of intent to sell 34,465 shares of | Oct 6, 2026 |
| RLAY | 144 | neutral | 3/10 | Thomas Catinazzo, an officer of Relay Therapeutics, filed a Form 144 notice of intent to sell up to 93,153 shares of com | Oct 6, 2026 |
| JAZZ | 144 | neutral | 2/10 | Renee D. Gala, an officer of Jazz Pharmaceuticals, filed a Form 144 notice of intent to sell 2,000 common shares with an | Oct 6, 2026 |
| MGTX | 144 | neutral | 3/10 | Stuart Naylor, an officer of MeiraGTx Holdings plc, filed a Form 144 on October 6, 2026, indicating intent to sell 27,65 | Oct 6, 2026 |
| ACHV | 3 | neutral | 2/10 | Benjamin Halladay filed a Form 3 initial statement of beneficial ownership upon becoming Chief Financial Officer of Achi | Oct 6, 2026 |
| IDYA | 144 | bearish | 6/10 | CEO Yujiro Hata filed a Form 144 notice of intent to sell shares of IDEAYA Biosciences, covering 8,804,981 shares acquir | Oct 6, 2026 |
| BOLT | 8-K | bearish | 6/10 | Bolt Biotherapeutics amended its lease to accelerate the expiration date to December 31, 2027 (or earlier upon a financi | Oct 6, 2026 |
| PTCT | 144 | neutral | 2/10 | Mark Elliott Boulding, an officer of PTC Therapeutics, filed a Form 144 notice of intent to sell 435 shares of common st | Oct 6, 2026 |
| CRBU | 8-K | bearish | 7/10 | Caribou Biosciences is discontinuing its two allogeneic CAR-T cell therapy programs (vispa-cel and CB-011), implementing | Oct 6, 2026 |
| KYNB | 8-K | bearish | 8/10 | Kyntra Bio received a delisting determination from Nasdaq on September 30, 2026, for failing to comply with Listing Rule | Oct 6, 2026 |
| UPC | 6-K | bearish | 5/10 | Universe Pharmaceuticals reported the results of its 2026 Annual General Meeting held on September 30, 2026, where all e | Oct 6, 2026 |
| ETON | 144 | neutral | 2/10 | David Krempa, an officer of Eton Pharmaceuticals, filed a Form 144 on October 6, 2026, indicating intent to sell 4,166 s | Oct 6, 2026 |
| NEOG | 8-K | bullish | 6/10 | Neogen reported Q1 FY2027 revenue of $222.8M (+6.5% YoY, +8.1% core growth), beating the $208.2M consensus, but GAAP EPS | Oct 6, 2026 |
| VIVS | 8-K | neutral | 4/10 | VivoSim Labs held its 2026 Annual Meeting on September 30, 2026. Stockholders approved a 3,165,000-share increase to the | Oct 6, 2026 |
| PLUR | S-1 | neutral | 3/10 | Pluri Inc. filed an S-1 registration statement to register 2,228,940 common shares for resale by Armistice Capital, LLC, | Oct 6, 2026 |
| VIR | 3 | neutral | 2/10 | Aziz Sawaf filed a Form 3 initial statement of beneficial ownership upon becoming EVP and Chief Financial Officer of Vir | Oct 6, 2026 |
| NGNE | SC 13G | neutral | 4/10 | Jennison Associates LLC disclosed a 5%+ passive stake in Neurogene Inc. via a Schedule 13G filing, reporting beneficial | Oct 6, 2026 |
| RXRX | 144 | neutral | 2/10 | Director Blake Borgeson filed a Form 144 notice of intent to sell 50,000 Class A shares of Recursion Pharmaceuticals, wi | Oct 6, 2026 |
| RXRX | 144 | neutral | 3/10 | Director Robert Hershberg filed a Form 144 notice to sell 25,000 Class A shares of Recursion Pharmaceuticals, with an es | Oct 6, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK plc filed a routine 6-K reporting the admission of 19,352 ordinary shares to trading on the London Stock Exchange un | Oct 6, 2026 |
| HYFT | 6-K | neutral | 3/10 | MindWalk Holdings Corp. issued a press release outlining its strategic positioning of ReefIQ as a biological context lay | Oct 6, 2026 |
| OTLK | PRESS-RELEASE | neutral | 3/10 | Outlook Therapeutics participated in a Virtual Investor segment featuring its new CFO Kevin Lundquist, who discussed the | Oct 6, 2026 |
| GRML | PRESS-RELEASE | neutral | 4/10 | Greenland Mines announced a $20 million share repurchase authorization, following recent capital raises totaling over $5 | Oct 6, 2026 |
| RGEN | 8-K | bullish | 6/10 | Repligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026. BioLife stockholders received $1 | Oct 6, 2026 |
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a collaboration with TychoBio, an AI drug discovery company, to generate full-length RNA data using Pac | Oct 6, 2026 |
| RGEN | PRESS-RELEASE | bullish | 6/10 | Repligen completed its acquisition of BioLife Solutions, paying $11.25 per share in cash plus 0.1442 shares of Repligen | Oct 6, 2026 |
| BIAF | 8-K | bullish | 5/10 | bioAffinity Technologies reported that sales of its CyPath Lung test more than doubled year-over-year through Q3 2026, w | Oct 6, 2026 |